Exploring how a new antibody therapy affects cancer treatment responses
Imaging the multifaceted response to a bispecific antibody therapy
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-10656275
This study is looking at a new treatment that uses a special type of antibody to help patients with advanced triple negative breast cancer and lung cancer, and it will also use imaging to see how well the treatment is working and who might benefit the most from it.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-10656275 on ClinicalTrials.gov |
What this research studies
This research investigates the effectiveness of a bispecific antibody therapy designed to target both the epidermal growth factor receptor (EGFR) and cMET receptor in patients with metastatic triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). The study aims to develop PET imaging biomarkers to monitor how well the therapy is delivered to tumors and how it alters receptor status in the body. By correlating imaging results with genetic mutation data, the research seeks to identify which patients are most likely to benefit from this innovative treatment approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic triple negative breast cancer or non-small cell lung cancer who may benefit from bispecific antibody therapy.
Not a fit: Patients with early-stage breast cancer or lung cancer who are not metastatic may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with metastatic TNBC and NSCLC.
How similar studies have performed: Other research has shown promise in using bispecific antibodies for cancer treatment, indicating potential for success with this approach.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MARQUEZ-NOSTRA, BERNADETTE — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: MARQUEZ-NOSTRA, BERNADETTE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer cell line, Cancer cell line